Proton pump inhibitors are often prescribed concomitantly with clopidogrel and aspirin to patients post-percutaneous coronary interventions and/or an acute coronary syndrome to mitigate the risk of potential gastrointestinal bleeding, associated primarily with clopidogrel use. Over the last several years, there have been data both supporting and refuting a clopidogrel-proton pump inhibitor interaction. This review critically considers the current evidence and provides practical recommendations to healthcare providers.
- Drug interaction
- Percutaneous coronary intervention
- Proton pump inhibitor
ASJC Scopus subject areas
- Molecular Medicine
- Pharmaceutical Science
- Cardiology and Cardiovascular Medicine